Page 110 - 《中国药房》2024年24期

Ann Intern Med，2023，176（2）：224-238. mone （1-84） for osteoporosis[J]. N Engl J Med，2005，353
[ 3 ] US Preventive Services Task Force，CURRY S J，KRIST （6）：555-565.
A H，et al. Screening for osteoporosis to prevent fractures： [15] COSMAN F，MILLER P D，WILLIAMS G C，et al. Eigh‐
US Preventive Services Task Force recommendation state‐ teen months of treatment with subcutaneous abaloparatide
ment[J]. JAMA，2018，319（24）：2521-2531. followed by 6 months of treatment with alendronate in
[ 4 ] DEARDORFF W J，CENZER I，NGUYEN B，et al. Time postmenopausal women with osteoporosis：results of the
to benefit of bisphosphonate therapy for the prevention of ACTIVExtend trial[J]. Mayo Clin Proc，2017，92（2）：
fractures among postmenopausal women with osteoporo‐ 200-210.
sis：a meta-analysis of randomized clinical trials[J]. JAMA [16] GREENSPAN S L，FITZPATRICK L A，MITLAK B，
Intern Med，2022，182（1）：33-41. et al. Abaloparatide followed by alendronate in women ≥
[ 5 ] CHENG C，WENTWORTH K，SHOBACK D M. New 80 years with osteoporosis：post hoc analysis of AC‐
frontiers in osteoporosis therapy[J]. Annu Rev Med，2020， TIVExtend[J]. Menopause，2020，27（10）：1137-1142.
71：277-288. [17] HAGINO H，SUGIMOTO T，TANAKA S，et al. A ran‐
[ 6 ] LANGDAHL B L，LIBANATI C，CRITTENDEN D B， domized，controlled trial of once-weekly teriparatide injec‐
et al. Romosozumab （sclerostin monoclonal antibody） tion versus alendronate in patients at high risk of osteopo‐
versus teriparatide in postmenopausal women with osteo‐ rotic fracture：primary results of the Japanese osteoporosis
porosis transitioning from oral bisphosphonate therapy：a intervention trial-05[J]. Osteoporos Int，2021，32（11）：
randomised，open-label，phase 3 trial[J]. Lancet，2017，390 2301-2311.
（10102）：1585-1594. [18] NANKI T，KAWAZOE M，UNO K，et al. Improvement in
glucocorticoid-induced osteoporosis on switching from
[ 7 ] SAUL D，DRAKE M T. Update on approved osteoporosis
therapies including combination and sequential use of bisphosphonates to once-weekly teriparatide：a rando-
agents[J]. Endocrinol Metab Clin North Am，2021，50（2）： mized open-label trial[J]. J Clin Med，2022，12（1）：292.
179-191. [19] RITTMASTER R S，BOLOGNESE M，ETTINGER M P，
et al. Enhancement of bone mass in osteoporotic women
[ 8 ] RASHKI KEMMAK A，REZAPOUR A，JAHANGIRI R，
et al. Economic burden of osteoporosis in the world：a with parathyroid hormone followed by alendronate[J]. J
systematic review[J]. Med J Islam Repub Iran，2020，34：154. Clin Endocrinol Metab，2000，85（6）：2129-2134.
[20] 包呼和，孙官文，王剑，等. 特立帕肽和双膦酸盐序贯治
[ 9 ] FINKELSTEIN J S，HAYES A，HUNZELMAN J L，et al.
The effects of parathyroid hormone，alendronate，or both 疗高龄骨质疏松症患者的疗效观察[J]. 实用临床医药杂
志，2021，25（16）：95-98.
in men with osteoporosis[J]. N Engl J Med，2003，349
BAO H H，SUN G W，WANG J，et al. Efficacy observa‐
（13）：1216-1226.
[10] COSMAN F，ERIKSEN E F，RECKNOR C，et al. Effects tion on sequential therapy with teriparatide and bispho-
of intravenous zoledronic acid plus subcutaneous teripara‐ sphonates for senile patients with osteoporosis[J]. J Clin
Med Pract，2021，25（16）：95-98.
tide[rhPTH（1-34）] in postmenopausal osteoporosis[J]. J [21] LOU S H，LV H C，WANG G Q，et al. The effect of se‐
Bone Miner Res，2011，26（3）：503-511. quential therapy for postmenopausal women with osteopo‐
[11] YANG D Z，TAN J，LONG Y F，et al. Sequential treat‐ rosis：a PRISMA-compliant meta-analysis of randomized
ment of teriparatide and alendronate versus alendronate
controlled trials[J]. Medicine，2016，95（49）：e5496.
alone for elevation of bone mineral density and prevention [22] LEDER B Z. Optimizing sequential and combined ana‐
of refracture after percutaneous vertebroplasty in osteopo‐
bolic and antiresorptive osteoporosis therapy[J]. JBMR
rosis：a prospective study[J]. Aging Clin Exp Res，2023，35
Plus，2018，2（2）：62-68.
（3）：531-539. [23] ERIKSEN E F，BROWN J P. Commentary：concurrent ad‐
[12] 中华医学会骨质疏松症和骨矿盐疾病分会. 原发性骨质
ministration of PTH and antiresorptives：additive effects
疏松症诊疗指南：2022[J]. 中华骨质疏松症和骨矿盐疾
or DXA cosmetics[J]. Bone，2016，86：139-142.
病杂志，2022，15（6）：573-611. [24] WHITMARSH T，TREECE G M，GEE A H，et al. Map‐
Chinese Society of Osteoporosis and Bone Mineral Re‐ ping bone changes at the proximal femoral cortex of post‐
search. Guidelines for diagnosis and treatment of primary menopausal women in response to alendronate and teripa‐
osteoporosis：2022[J]. Chin J Osteoporos Bone Miner ratide alone，combined or sequentially[J]. J Bone Miner
Res，2022，15（6）：573-611. Res，2015，30（7）：1309-1318.
[13] ACOG Committee on Clinical Practice Guidelines- [25] FINKELSTEIN J S，WYLAND J J，LEE H，et al. Effects
gynecology. Management of postmenopausal osteoporo‐ of teriparatide，alendronate，or both in women with post‐
sis：ACOG clinical practice guideline No. 2[J]. Obstet menopausal osteoporosis[J]. J Clin Endocrinol Metab，
Gynecol，2022，139（4）：698-717. 2010，95（4）：1838-1845.
[14] BLACK D M，BILEZIKIAN J P，ENSRUD K E，et al. （收稿日期：2024-06-23 修回日期：2024-10-04）
One year of alendronate after one year of parathyroid hor‐ （编辑：舒安琴）

· 3064 · China Pharmacy 2024 Vol. 35 No. 24 中国药房 2024年第35卷第24期